Skip to main content

Trispecific Antibody Deal Benchmarks in Oncology

Median Upfront
$258M
Range: $144M - $365M
Total Deal Value
$1.6B
Range: $1.1B - $2.2B
Royalty Rate
11.8% - 19.3%
Tiered up to 23.3%
Dev Milestones
$345M
Range: $230M - $461M
Model Your Deal

Market Analysis

Trispecific Antibody therapies in oncology have seen significant M&A and licensing activity in recent years. Based on analysis of 1,500+ verified transactions, the median upfront payment for a Phase 2 trispecific antibody asset in oncology is $258M, with total deal values reaching $1.6B. Development milestones average $345M, while regulatory milestones contribute $552M.

The oncology trispecific antibody landscape is characterized by high competitive intensity with numerous active programs and a rapidly evolving standard of care. ADCs, bispecifics, and radiopharmaceuticals continue to drive premium valuations across solid and hematologic tumors. The recommended deal structure allocates approximately 16% to upfront payments and 84% to milestones, reflecting the risk-reward profile at the Phase 2 stage.

Royalty rates for trispecific antibody oncology deals range from 11.8% to 19.3% at the base tier, with tiered escalation reaching 15.8%-23.3% on blockbuster sales. Commercial milestones averaging $483M further reward successful market penetration.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the typical upfront for a trispecific antibody oncology licensing deal?
Based on our analysis, Phase 2 trispecific antibody licensing deals in oncology average $258M in upfront payments, with a range of $144M to $365M depending on data quality, competitive positioning, and territorial scope.
What is the total deal value for trispecific antibody oncology transactions?
The median total deal value for Phase 2 trispecific antibody assets in oncology is $1.6B, ranging from $1.1B to $2.2B. This includes development milestones ($345M), regulatory milestones ($552M), and commercial milestones ($483M).
What royalty rates are standard for trispecific antibody deals in oncology?
Base royalty rates for trispecific antibody oncology transactions range from 11.8% to 19.3%, with tiered escalations reaching 15.8%-23.3% on peak sales. Rates are influenced by mechanism differentiation, competitive landscape, and territorial scope.
How are milestones structured in trispecific antibody oncology deals?
Trispecific Antibody oncology deals allocate approximately 84% of total deal value to milestones. Development milestones ($345M) make up the largest share, followed by commercial milestones ($483M) and regulatory milestones ($552M).
PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Related Benchmarks

Small Molecule in Oncology

View

Monoclonal Antibody in Oncology

View

Trispecific Antibody in Neurology

View

Trispecific Antibody in Hematology

View

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.

Start Calculating
For Funds & Advisors

Need the full deal landscape?

The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.

Configure Brief — $2,500All-inclusive · White-label · Walkthrough included